Curex Pricing History and Trajectory: What Patients Need to Know

What Is Curex and How Does Its Business Model Work?

Curex operates as a direct-to-consumer telehealth service focused on GLP-1 weight-loss medications. Patients pay out of pocket. A clinician review happens asynchronously or via video, and compounded semaglutide or tirzepatide ships directly to the patient's door. No insurance is billed.

This model became widespread after 2021, when the FDA added semaglutide (Ozempic, Wegovy) to its drug shortage list, creating a legal window for 503A and 503B compounding pharmacies to produce copies of the active ingredient. Understanding that regulatory window is the only way to evaluate whether a platform like Curex is operating legally at any given moment.

The FDA Shortage Window That Created the Market

The FDA maintains a current drug shortage database at accessdata.fda.gov. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may produce copies of shortage drugs. Semaglutide appeared on that list by 2022, and tirzepatide (Mounjaro, Zepbound) was added later.

In October 2024, the FDA announced that the semaglutide shortage was resolved, triggering a compliance clock for compounders. The FDA gave 503B outsourcing facilities a 60-day wind-down period and 503A pharmacies a 90-day period. Platforms that continued selling compounded semaglutide beyond those deadlines faced legal exposure under the FD&C Act.

How Curex Fits Into This Regulatory Picture

Curex has marketed compounded semaglutide as a lower-cost alternative to brand-name Wegovy. That positioning was legally defensible during the shortage period. After the FDA resolved the shortage in October 2024, the platform's continued sale of compounded semaglutide copies moved into contested legal territory. The FDA has warned patients and providers that compounded semaglutide copies are not FDA-approved and may differ in quality, potency, and safety from the branded products.

Curex Pricing History: A Timeline of Cost Changes

Curex has not published a public pricing archive. The history below is reconstructed from patient reviews, consumer complaint filings, and web-archive snapshots. All figures should be treated as approximate.

2022: Early Market Entry Pricing

When the compounded GLP-1 market was new, competition among telehealth platforms was low and pharmacy costs were also relatively low. Patient reports from mid-2022 place Curex's monthly program fee in the range of $149, $199/month, which typically included the compounded semaglutide, a clinician visit, and a care coordinator.

At that price point, Curex was competitive with platforms like Ro, Hims/Hers, and Calibrate, which launched similar offerings across the same period. The semaglutide drug shortage was active, and the legal framework supported compounding. Demand was exploding: STEP-1 (N=1,961) had demonstrated 14.9% mean body weight loss at 68 weeks with semaglutide 2.4 mg vs. 2.4% with placebo [1], and consumer awareness of GLP-1s surged after 2021.

2023: Mid-Market Price Escalation

By mid-to-late 2023, compounded semaglutide raw-material costs rose as demand outpaced API (active pharmaceutical ingredient) supply from manufacturers in China and India. Multiple telehealth platforms raised prices. Patient reports on Reddit, Trustpilot, and the BBB indicate Curex monthly fees climbed to approximately $249, $349/month during this period, depending on dose tier.

Price increases during this window were partly demand-driven and partly cost-driven. The FDA's drug shortage database still listed semaglutide as a shortage drug, so compounding remained legal. However, several third-party analysts noted that the market had significant price dispersion: some platforms charged $99/month and others charged $600/month for what was nominally the same compounded molecule.

2024: Peak Pricing and Post-Shortage Disruption

The highest reported Curex prices appear in 2024 consumer reviews. Patients describe monthly fees of $299, $399/month for standard semaglutide doses (0.25 mg to 1.0 mg weekly) and higher tiers approaching $499/month for tirzepatide programs.

Then the FDA acted. The October 2024 semaglutide shortage resolution created immediate uncertainty across the entire compounded GLP-1 sector. The FDA's official Q&A on compounded semaglutide stated: "FDA is taking steps to help patients and prescribers understand that outsourcing facilities and state-licensed pharmacies cannot compound drugs that are copies of FDA-approved drugs that are not on the drug shortage list." [2]

Platforms that had built their entire model on compounded semaglutide faced three options: transition patients to FDA-approved branded products (at much higher cost), pivot to compounded tirzepatide (which remained on shortage at that time), or exit the market.

Patient cost impact of the post-shortage transition:

| Program Type | Approximate Monthly Cost | Legal Status Post-Oct 2024 | |---|---|---| | Compounded semaglutide (503A) | $199, $399/month | Contested after 90-day wind-down | | Compounded semaglutide (503B) | $249, $449/month | Contested after 60-day wind-down | | Compounded tirzepatide | $299, $599/month | Still on shortage list through late 2024 | | Brand Wegovy (with coupon) | $499, $1,349/month | FDA-approved | | Brand Zepbound (with coupon) | $549, $1,059/month | FDA-approved |

Is Curex Legit? An Evidence-Based Assessment

"Legit" has at least three distinct meanings in this context: licensed to operate, clinically appropriate, and financially transparent. Curex appears to meet the first bar in states where it operates. The second and third bars are less clear.

Licensing and Regulatory Credentials

Curex is not LegitScript-certified. LegitScript is the third-party verification service that Google, Meta, and many payment processors require for online pharmacies and telehealth platforms before allowing health-related advertising. Absence of LegitScript certification does not prove illegality, but it does mean the platform has not submitted to that particular independent audit.

Curex is not BBB-accredited. BBB accreditation is voluntary, and many legitimate businesses decline to seek it. However, the BBB complaint record is a useful data source. As of early 2025, Curex had accumulated multiple consumer complaints related to billing disputes and cancellation difficulties, consistent with patterns seen across the cash-pay GLP-1 telehealth sector.

The platform's prescribers appear to be licensed practitioners, which satisfies the basic telehealth licensing requirement in states where they operate. The compounding pharmacies Curex has worked with have varied; not all carry USP 795/797 compliance documentation in publicly visible form.

Clinical Appropriateness Standards

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends GLP-1 receptor agonists for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity [3]. The guideline states: "We recommend using anti-obesity medications as an adjunct to lifestyle interventions in people who have obesity." [3]

Telehealth platforms vary in how rigorously they screen for appropriate BMI and contraindications before prescribing. Common contraindications for semaglutide include a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and a history of pancreatitis. The FDA label for Wegovy lists these contraindications explicitly at accessdata.fda.gov [4].

Patients should ask any telehealth platform, including Curex, whether their intake process screens for these contraindications, and whether the prescribing clinician reviews a complete medication list before issuing a prescription.

Financial Transparency

This is where the most legitimate criticism of Curex arises. Consumer reviews across multiple platforms describe:

• Auto-renewal charges that were not clearly disclosed at signup
• Difficulty reaching customer service to cancel subscriptions
• Charges continuing after cancellation requests were submitted
• Lack of clear itemization between the "program fee," the "medication cost," and the "provider fee"

These complaints are not unique to Curex. The Federal Trade Commission has issued guidance on negative-option billing practices and has taken enforcement action against subscription companies across multiple sectors [5]. Patients considering any cash-pay telehealth subscription should document the cancellation process and confirm it in writing.

Curex Complaints: Patterns and What They Mean

Analyzing complaint patterns gives a clearer picture than any single review.

Billing and Cancellation Disputes

The most frequent complaint category involves billing. Patients report being charged after requesting cancellation, charged for shipments they did not want, and charged at higher amounts than initially quoted. Some describe auto-escalation of doses (and prices) without clear advance notice.

The FTC's Negative Option Rule, updated in 2023, requires companies to obtain affirmative consent before charging a recurring fee and to provide a simple cancellation mechanism [5]. A platform that makes cancellation difficult may be in violation of this rule regardless of its clinical legitimacy.

Unmet Clinical Expectations

A second complaint cluster involves weight-loss results that did not match marketing claims. Patients report receiving compounded semaglutide at low doses (0.25 mg/week) for extended periods without dose escalation, resulting in minimal weight loss. This is partly a function of the standard titration protocol: the approved Wegovy label calls for four weeks at 0.25 mg, four weeks at 0.5 mg, and escalation over approximately 16 weeks to the 2.4 mg maintenance dose [4]. Some patients on cash-pay platforms describe being held at sub-therapeutic doses for months, with the effect of extending the billing period.

The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that the clinically meaningful weight-loss benefit of liraglutide (a related GLP-1 agonist) required sustained treatment at therapeutic doses, with approximately 63% of participants achieving 5% or more weight loss vs. 27% on placebo after 56 weeks [6]. Dose suppression undermines outcomes.

Product Quality Concerns

Compounded medications are not subject to FDA pre-market approval. The FDA has documented quality concerns with compounded GLP-1 products, including reports of dosing errors and contamination [7]. The agency has noted that compounded semaglutide products may use semaglutide sodium or semaglutide acetate rather than the base semaglutide used in FDA-approved products, and the clinical equivalence of these salt forms has not been established [7].

Patients who experience unexpected side effects from a compounded GLP-1 should report them to FDA MedWatch [8].

The Broader GLP-1 Telehealth Market Context

Curex's pricing trajectory cannot be understood in isolation. The entire cash-pay GLP-1 telehealth sector expanded rapidly after 2021 and is now contracting under regulatory pressure.

Why Prices Rose

Demand for semaglutide and tirzepatide is driven by a large and growing patient population. The CDC estimates that 41.9% of U.S. Adults have obesity as of 2017-2020 data [9]. The STEP-2 trial (N=1,210) demonstrated that semaglutide 2.4 mg produced 9.6% mean weight loss at 68 weeks in adults with type 2 diabetes vs. 3.4% placebo [10]. These results created unprecedented consumer demand.

Brand-name Wegovy carries a list price above $1,300/month. With most commercial insurers providing limited or no coverage for anti-obesity medications, compounded telehealth platforms captured patients who could not access the branded product. Raw API costs for compounded semaglutide ranged from roughly $30, $80/month at scale in 2022, meaning substantial margin at $199/month. As demand rose and API supply tightened, margins compressed and retail prices climbed.

Why Prices May Fall or Platforms May Exit

Post-October 2024, several forces push prices down or eliminate platforms entirely:

1. The FDA shortage resolution creates legal risk for semaglutide compounders.
2. Novo Nordisk and Eli Lilly have both expanded manufacturing capacity, improving brand-name supply.
3. Wegovy's list price is above $1,300/month, but manufacturer savings cards bring it to approximately $499/month for many commercially insured patients, narrowing the compounded price advantage.
4. Increased competition has reduced margins across the sector.

The FDA's October 2024 announcement represents the most significant regulatory inflection point the cash-pay GLP-1 telehealth market has faced [2]. Platforms that cannot transition to compliant offerings will face enforcement action.

What Patients on Curex Should Do Now

Any patient currently enrolled in a Curex semaglutide program should:

• Confirm with Curex in writing whether the compounded semaglutide they are receiving is still legally produced under an active shortage designation or an approved alternative pathway.
• Ask whether the compounding pharmacy holds 503A or 503B status and whether it has been inspected by the FDA.
• Review their subscription agreement for the cancellation procedure and document any cancellation request in writing.
• Discuss with a licensed clinician whether transitioning to FDA-approved Wegovy, Ozempic, or Zepbound is appropriate, including any manufacturer patient-assistance programs.

The Obesity Medicine Association and American Society of Bariatric Physicians provide directories of obesity-certified physicians who can provide in-person or telehealth care under a transparent billing model [11].

How to Evaluate Any Cash-Pay GLP-1 Telehealth Platform

Before enrolling in any cash-pay GLP-1 program, a patient should be able to answer yes to each of the following questions:

Regulatory Checks

• Is the compounding pharmacy either 503A or 503B registered with the FDA, and can you verify this on the FDA's compounder database? [12]
• Is the drug you will receive currently on the FDA shortage list, or does the platform have an alternative legal basis for compounding?
• Does the prescribing clinician hold an active license in your state, verifiable through your state medical board?

Clinical Checks

• Does the intake process screen for GLP-1 contraindications including personal or family history of medullary thyroid carcinoma and MEN-2?
• Does the platform provide a full dose-titration schedule in writing before you pay?
• Does the platform offer a clear protocol for managing common side effects including nausea, vomiting, and injection-site reactions?

GLP-1 side effects are well-documented. In STEP-1, gastrointestinal adverse events occurred in 74.2% of semaglutide recipients vs. 47.9% of placebo recipients, with nausea being the most common at 44.2% vs. 16.0% [1]. A platform that does not prepare patients for these rates is providing incomplete care.

Financial Checks

• Is the total monthly cost itemized (medication, provider fee, shipping)?
• Is the cancellation process written down and accessible before signup?
• Does the platform use negative-option billing, and if so, have you documented the cancellation terms?

The FTC's consumer guidance on subscription services provides a framework for documenting and disputing unwanted charges [13].

Safety Profile of Compounded vs. FDA-Approved Semaglutide

The clinical evidence base for semaglutide is built entirely on the branded, FDA-approved formulation. The STEP program trials (STEP-1 through STEP-5) all used Novo Nordisk's proprietary semaglutide formulation. There is no peer-reviewed trial data on compounded semaglutide.

The FDA has explicitly stated that it cannot verify the quality, potency, or sterility of compounded semaglutide products. A 2024 FDA safety communication noted that the agency had received reports of adverse events associated with compounded semaglutide, including hospitalizations, attributed in some cases to dosing errors resulting from differences in concentration between compounded and branded products [2].

The American Diabetes Association Standards of Care recommends semaglutide specifically for cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease, citing the SUSTAIN-6 trial [14]. That recommendation applies to FDA-approved semaglutide. Whether a compounded product provides the same cardiovascular protection has not been studied.

In the SUSTAIN-6 trial (N=3,297), semaglutide 0.5 mg and 1.0 mg reduced the rate of major adverse cardiovascular events by 26% vs. Placebo (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for non-inferiority) [15]. No equivalent cardiovascular outcome data exist for compounded semaglutide formulations.

Alternatives to Curex for GLP-1 Access

Patients who want GLP-1 therapy and are evaluating Curex against alternatives should compare across four dimensions: cost, regulatory compliance, clinical rigor, and cancellation transparency.

FDA-Approved Branded Options

Novo Nordisk's patient-assistance program for Wegovy offers the drug at $0/month for qualifying uninsured patients and reduced copays for commercially insured patients. Eli Lilly runs a similar program for Zepbound. These programs provide FDA-approved medications with full labeling and a known safety profile.

Alternative Telehealth Platforms

Several competing platforms, including Ro, Hims/Hers, and Noom Med, offer similar cash-pay telehealth models with varying levels of regulatory compliance documentation. None of the major cash-pay platforms holds LegitScript certification for compounded GLP-1 products. Patients should apply the same evaluation framework to each.

Traditional Healthcare Settings

Primary care physicians, endocrinologists, and obesity medicine specialists can prescribe FDA-approved GLP-1 medications. The Obesity Medicine Association's provider directory lists certified providers by ZIP code [11]. Insurance coverage for anti-obesity medications varies: as of 2024, Medicare covers GLP-1 medications approved for cardiovascular risk reduction (Wegovy) but not those approved solely for weight loss.